Leukemia, Myeloid, Acute

Oncology·MeSH: Leukemia, Myeloid, Acute

Prevalence

30.0 / 100K

11 drugs in development·6 companies·9 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
azacitadine	GH Research PLC (GHRS)
Cytarabine	Merus N.V. (MRUS)
Cytarabine + Daunorubicin + Gilteritinib	Merus N.V. (MRUS)

Phase 2(3)

Phase 1(2)

Drug	Company
Bleximenib	Merus N.V. (MRUS)
jnj-90189892	GH Research PLC (GHRS)

Phase 1/Phase 2(1)

Drug	Company
mb-dnpm1-tcr.1	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)

Phase 2/Phase 3(2)

Drug	Company
annamycin	Moleculin Biotech, Inc. (MBRX)
liposomal annamycin	Moleculin Biotech, Inc. (MBRX)

BioSniper tracks 11 drugs in development for Leukemia, Myeloid, Acute across 6 companies.

There are 9 clinical trials targeting Leukemia, Myeloid, Acute tracked by BioSniper.

The estimated prevalence of Leukemia, Myeloid, Acute is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.